Patents Assigned to LEIBNIZ INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V.
  • Patent number: 11485721
    Abstract: The present invention relates to a method for the metal-free preparation of a biaryl compound by a photosplicing reaction and its use in the preparation of chemical compounds, preferably of active ingredients e.g. in the fields of pharmaceuticals and agrochemicals. In particular, it refers to a method for the regiocontrolled preparation of a biaryl compound of formula (I): Ar—Ar? by photochemically reacting a precursor compound of formula (II): Ar—L—Ar? to form a biaryl compound of general formula: Ar—L—Ar?(II)?Ar—Ar? (I) wherein Ar and Ar?, independently of each other, represent an unsubstituted or substituted C6-C20 aryl group or a heteroaryl group with 5-20 ring atoms selected from carbon, nitrogen, oxygen and sulfur, and L represents a group —X—Y—Z— as defined herein. The biaryl compounds are generally suitable as intermediates or key building blocks in a very broad spectrum of organic chemical syntheses and their respective utilities.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: November 1, 2022
    Assignee: Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut
    Inventors: Florian Kloss, Toni Neuwirth, Veit Haensch, Christian Hertweck
  • Patent number: 9969796
    Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: May 15, 2018
    Assignees: KING'S COLLEGE LONDON, LEIBNIZ INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V.
    Inventors: Julian Naglik, David Moyes, Shirley Tang, Bernhard Hube, Duncan Wilson, Sarah Hofs, Jonathan Richardson
  • Publication number: 20160046699
    Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.
    Type: Application
    Filed: April 10, 2014
    Publication date: February 18, 2016
    Applicants: KING'S COLLEGE LONDON, LEIBNIZ INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V.
    Inventors: Julian NAGLIK, David MOYES, Shirley TANG, Bernhard HUBE, Duncan WILSON, Sarah HOFS, Jonathan RICHARDSON